Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Equasens Société anonyme (0R9T) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Equasens Société anonyme €52.96, price €29.65, upside +78.6%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
ES
Some data
Oct 2, 2026
Equasens Société anonyme
0R9T · LSEClearly undervaluedStrong Fair Value upside, but quality is only moderate.
✓Fair value €52.96 · Strongly undervalued (+78.6%)
✓Quality 67/100
✓Healthy Growth (revenue 5y +6.6 %/yr)
✓Solidly profitable · 16.6% net margin (TTM)
✓Low debt · generates free cash flow
✓4.7% dividend yield · Well covered
✓Wide moat 66/100
!Evidence only medium, so the estimate is less certain
Watch Equasens Société anonyme for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range €28.90 – €91.66 · fair‑value band €37.69 – €66.54 · the €29.65 price screens below the €52.96 fair value. Dashed = 300-day average. As of Oct 2, 2026.
Company profile
Equasens provides healthcare IT solutions in Europe. The company publishes software and connected solutions for pharmacies, medical-social establishments, doctors, and medical auxiliaries. It also manufactures connected electronic devices and appliances for healthcare professionals and patients.
Show more
Equasens provides healthcare IT solutions in Europe. The company publishes software and connected solutions for pharmacies, medical-social establishments, doctors, and medical auxiliaries. It also manufactures connected electronic devices and appliances for healthcare professionals and patients. In addition, the company is financing solutions for rental properties for healthcare professionals and other tertiary sectors. It serves healthcare facilities and private healthcare professionals. The company was incorporated in 1996 and is headquartered in Villers-lès-Nancy, France. Equasens operates as a subsidiary of Marque Verte Sante.
Stock analysis
Equasens Société anonyme (0R9T) currently trades at €29.65, while our model-based Fair Value estimate is €52.96, implying the stock looks roughly 44.0% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €54.75 per share, and 18 of the 26 models we run sit above the €29.65 price.
Bear case: the Asset-Based group reads lowest at €11.31, and 8 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: €37.69 (bear) to €66.54 (bull), the price of €29.65 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Equasens Société anonyme reported revenue of €237M in FY2025 versus €193M in FY2021, a compound +5.2%/yr. Reported net income was €39.3M in FY2025, compounding +0.1%/yr from FY2021.
Key figures
Market cap €581M · P/E ratio 0.1 · P/S ratio 0.02 · EPS (TTM) €2.58 · Dividend yield 4.7% · Net margin 16.6% · Return on equity 16.3% · Return on assets (EBIT) 13.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 79%, 0R9T screens cheaper than that median.
Fair Value models
Bear €37.69
Fair Value €52.96
Bull €66.54
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.8923 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
€36.70
€54.75
€79.27
80
Growth DCF
€36.83
€52.32
€71.96
79
Owner Earnings
€34.26
€51.15
€74.10
76
All 26 models by family
DCF Models
FCF DCF
€36.70
€54.75
€79.27
80
Owner Earnings
€34.26
€51.15
€74.10
76
5Y Revenue Exit
€30.38
€47.19
€68.44
72
5Y EBITDA Exit
€38.28
€62.15
€90.02
75
5Y P/E Exit
€36.95
€59.63
€83.52
70
10Y Revenue Exit
€31.78
€46.97
€67.10
67
10Y EBITDA Exit
€37.16
€56.52
€82.32
68
10Y P/E Exit
€36.38
€54.91
€77.73
64
Earnings-Based
Graham-Dodd
€17.88
€59.34
€79.41
64
Lynch FV
€13.42
€19.17
€24.92
61
PEG = 1.0
€13.42
€19.17
€24.92
57
EPV
€18.50
€21.21
€23.47
74
Dividend Discount
Gordon GGM
€9.76
€17.59
€24.22
68
DDM Multi-Stage
€9.76
€15.63
€18.79
67
Multiples
P/E Multiple
€43.39
€57.85
€72.31
63
P/S Multiple
€33.53
€44.70
€55.88
58
P/B Multiple
€33.53
€44.70
€55.88
55
EV/EBIT
€39.32
€52.89
€66.46
66
EV/EBITDA
€44.47
€59.76
€75.05
67
EV/Revenue
€27.66
€40.11
€52.57
53
Asset-Based
NCAV (Graham)
€8.44
€11.31
€16.88
54
Growth DCF
Growth DCF
€36.83
€52.32
€71.96
79
Rev-Margin DCF
€30.38
€47.45
€67.51
72
Economic Profit
Residual Income
€16.15
€19.65
€26.97
76
ROIC Compounder
€18.88
€23.16
€28.18
72
Growth Earnings
Growth-Adj P/E
€36.50
€52.15
€67.79
67
Notify me when 0R9T reaches fair value
Put 0R9T on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
67/100
Of which business quality 66 · Market factors (momentum, volatility) 29
Profitability
49
Margins and returns on capital today
Quality Growth
48
Are margins and returns improving?
Cashflow
89
Earnings quality: real cash, not paper profit
Fin. Strength
80
Balance sheet, leverage, solvency risk
Investment
78
Disciplined investing over empire-building
Low Volatility
62
Calm price path (market factor)
Momentum
21
Price trend over the last 3–12 months (market factor)
52W Momentum
7
Distance to the 52-week high (market factor)
Net Issuance
46
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
83/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic). Over 10 years: +7.6% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+9.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.1%
Dividend (yield on the price)4.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 20%
Watch 0R9T, get fair value alerts →
Compare Equasens Société anonyme with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 128 stocks
Beats the industry median on 10/11 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Health Information Services median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $278.57 | $306.43 | +10% |
| Pro Medicus Limited PME | A$161.00 | A$84.62 | −47% |
| BrightSpring Health Services, Inc BTSG | $56.54 | $25.86 | −54% |
| Hinge Health, Inc HNGE | $95.57 | $51.25 | −46% |
| HealthEquity, Inc HQY | $88.44 | $97.28 | +10% |
| Waystar Holding WAY | $24.70 | $27.17 | +10% |
| Doximity, Inc DOCS | $26.35 | $31.41 | +19% |
| XtalPi Holdings 2228 | HK$7.75 | HK$1.50 | −81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,779 | ₹1,883 | +6% |
| Privia Health Group PRVA | $19.62 | $5.02 | −74% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Equasens Société anonyme (0R9T) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of €52.96 versus a price of €29.65, about +79% upside (undervalued).
What is the fair value of 0R9T?
Our model-based fair value for Equasens Société anonyme is €52.96 (as of Oct 2, 2026), built from audited fundamentals. The current price: €29.65.
What is the quality score of 0R9T?
Equasens Société anonyme has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Equasens Société anonyme (0R9T)?
Our model-based price target is the fair value of €52.96 (as of Oct 2, 2026) from 26 valuation models. Cautious scenario €37.69, optimistic scenario €66.54. It is a calculation from audited fundamentals, not an analyst target.
What is the Equasens Société anonyme stock forecast for 2026?
Our models put fair value at €52.96, about +79% upside versus a price of €29.65 (undervalued). Cautious scenario €37.69, optimistic scenario €66.54. The calculation is refreshed regularly with new filings.
What is the revenue of Equasens Société anonyme (0R9T)?
Equasens Société anonyme reported trailing-twelve-month revenue of about €237M (latest available figure, as of Oct 2, 2026).
Does Equasens Société anonyme pay a dividend?
Equasens Société anonyme currently shows a dividend yield of about 4.72% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of Equasens Société anonyme (0R9T)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Equasens Société anonyme it is €52.96 per share (as of Oct 2, 2026), against a price of €29.65. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Equasens Société anonyme stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 0R9T trades below its calculated fair value: price €29.65, fair value €52.96, a gap of about +79% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0R9T?
No. The price is what the market pays today (€29.65); the fair value is what the company's own numbers justify (€52.96). For Equasens Société anonyme the two are €23.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is Equasens Société anonyme worth?
The market values Equasens Société anonyme at about €581M (market capitalisation, as of Oct 2, 2026). Per share that is €29.65; our models calculate a fair value of €52.96 per share.
What do the bullish and bearish scenarios say about 0R9T?
Our models span a range for Equasens Société anonyme: cautious scenario €37.69, base €52.96, optimistic €66.54 per share (as of Oct 2, 2026, price €29.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0R9T?
Equasens Société anonyme trades at a price-to-earnings ratio of 0.1 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €52.96 is built from several models across several years.
How solid is the balance sheet of Equasens Société anonyme (0R9T)?
Balance-sheet figures for Equasens Société anonyme (as of Oct 2, 2026): return on equity 16.3%, debt of 0.22 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 0R9T from its 52-week high?
Equasens Société anonyme trades at €29.65, about 34% below its 52-week high of €44.95 and 3% above the low of €28.90 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €52.96 is for.
Which stocks are comparable to Equasens Société anonyme?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Equasens Société anonyme stock attractive at the current price?
The data as of Oct 2, 2026: price €29.65, calculated fair value €52.96 (+79%), Quality Score 67/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0R9T calculated?
We run Equasens Société anonyme through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €52.96, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Equasens Société anonyme currently trades 44 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Equasens Société anonyme (0R9T)?
The closing price on Oct 2, 2026 was €29.65. Our model-based fair value is €52.96, about +79% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Equasens Société anonyme right now?
The price is below even our cautious bear case (€37.69). The market is more pessimistic than our downside scenario. Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Equasens Société anonyme (0R9T) come from?
Earnings per share at Equasens Société anonyme grew +22.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.6 %, EBIT margin −0.9 %, tax rate +8.0 %, residual (interest, one-offs) +6.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Equasens Société anonyme
How large is the market capitalisation of Equasens Société anonyme (0R9T)?
The market capitalisation of Equasens Société anonyme is €581M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Equasens Société anonyme (0R9T)?
The price-to-sales ratio of Equasens Société anonyme is 0.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Equasens Société anonyme (0R9T)?
Earnings per share at Equasens Société anonyme are €2.58 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Equasens Société anonyme (0R9T)?
The dividend yield of Equasens Société anonyme is 4.7% (payout 54.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Equasens Société anonyme (0R9T)?
The net margin of Equasens Société anonyme is 16.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Equasens Société anonyme (0R9T)?
The return on equity (ROE) of Equasens Société anonyme is 16.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Equasens Société anonyme (0R9T)?
On an EBIT basis the return on assets of Equasens Société anonyme is 13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Equasens Société anonyme (0R9T)?
The operating margin of Equasens Société anonyme is 22.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Equasens Société anonyme (0R9T)?
Revenue at Equasens Société anonyme is growing +10.8% versus a year earlier (3y avg +3.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Equasens Société anonyme (0R9T)?
Earnings per share at Equasens Société anonyme are growing +15.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Equasens Société anonyme (0R9T) generate?
The free cash flow of Equasens Société anonyme is €58.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Equasens Société anonyme (0R9T) carry?
The net debt of Equasens Société anonyme is €19.7M (fiscal year 2025, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Equasens Société anonyme in the live analysis
One click puts Equasens Société anonyme on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.